Tumor microenvironment-derived serum markers as a new frontier of diagnostic and prognostic assessment in biliary tract cancers.

"Conflict of interest:: The authors declare no conflict of interest. TFB is founder and advisor of Alentis Therapeutics, a biotech company developing monoclonal antibodies for treatment of solid tumors including hepatobiliary cancers."

"The authors acknowledge research support by the European Union (ERC-AdG-2020-FIBCAN #101021417, ERC-2022-PoC1 CANDY #101069276 to T.F.B.) FONDATION ARC – www.fondation-arc.org (TheraHCC2.0 IHU201901299), the Inserm Plan Cancer 2019–2023, the US National Institute of Health (R01CA233794), the French state funds managed within the “Plan Investissements d’Avenir” and by the ANR (references ANR-10-IAHU-02 and ANR-10-LABX-0028), along with French state funds managed by the ANR within the France 2030 program (reference ANR-21-RHUS-0001). This work of the Interdisciplinary Thematic Institute IMCBio, as part of the ITI 2021-2028 program of the University of Strasbourg, CNRS and Inserm, was supported by IdEx Unistra (ANR-10-IDEX-0002), and by SFRI-STRAT’US project (ANR 20-SFRI-0012) and EUR IMCBio (ANR-17-EURE-0023) under the framework of the French Investments for the Future Program."